Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News — ...
TAS-102 plus bevacizumab is cost-effective in China but not in the US or UK due to high incremental cost-effectiveness ratios (ICERs). The study uses a decision model to compare TAS-102 monotherapy ...
Adam Bress, PharmD, MS, explains what cost-effectiveness means as it pertains to cardiovascular disease and highlights measures used to capture information and make treatment decisions. Transcript ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback